The role of leukotrienes in airway inflammation

Yoshiko Ogawa, William Calhoun

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Cysteinyl leukotrienes (cysLTs) are a class of closely structurally related lipid molecules, originally described as slow-reacting substance of anaphylaxis, with a myriad of biologic functions. These activities include producing smooth muscle contraction and mucus secretion, recruiting allergic inflammatory cells, modulating cytokine production, influencing neural transmission, and altering structural changes in the airway. Administration of cysLTs to animals and human subjects reproduces many features of allergic inflammation and asthma. Leukotriene (LT) blockers have independent efficacy in asthma and improve pulmonary function when added to inhaled steroids. Conversely, blockade of this pathway both in animals and in human subjects results in important reductions in inflammation and its consequences and might reduce structural changes of remodeling. These data collectively make a compelling case for an important role of cysLTs in airway inflammation and asthma. However, the magnitude of effect of anti-LTs is smaller than that of corticosteroids, and there is more variability in benefit of LT blockade than is seen with inhaled steroids. In addition, adding anti-LTs to inhaled steroids in asthmatic patients does not appear to produce added anti-inflammatory benefit. Genetic polymorphisms and environmental factors, such as tobacco smoke exposure, might underlie some of the heterogeneity of response to LT blockers.

Original languageEnglish (US)
Pages (from-to)789-798
Number of pages10
JournalJournal of Allergy and Clinical Immunology
Volume118
Issue number4
DOIs
StatePublished - Oct 2006

Fingerprint

Leukotrienes
Asthma
Steroids
Inflammation
SRS-A
Genetic Polymorphisms
Mucus
Muscle Contraction
Smoke
Synaptic Transmission
Tobacco
Smooth Muscle
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Cytokines
Lipids
Lung
cysteinyl-leukotriene

Keywords

  • asthma
  • Cysteinyl leukotrienes
  • inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The role of leukotrienes in airway inflammation. / Ogawa, Yoshiko; Calhoun, William.

In: Journal of Allergy and Clinical Immunology, Vol. 118, No. 4, 10.2006, p. 789-798.

Research output: Contribution to journalArticle

@article{a6cecf090c30402a8d7e54f17dd1e7bc,
title = "The role of leukotrienes in airway inflammation",
abstract = "Cysteinyl leukotrienes (cysLTs) are a class of closely structurally related lipid molecules, originally described as slow-reacting substance of anaphylaxis, with a myriad of biologic functions. These activities include producing smooth muscle contraction and mucus secretion, recruiting allergic inflammatory cells, modulating cytokine production, influencing neural transmission, and altering structural changes in the airway. Administration of cysLTs to animals and human subjects reproduces many features of allergic inflammation and asthma. Leukotriene (LT) blockers have independent efficacy in asthma and improve pulmonary function when added to inhaled steroids. Conversely, blockade of this pathway both in animals and in human subjects results in important reductions in inflammation and its consequences and might reduce structural changes of remodeling. These data collectively make a compelling case for an important role of cysLTs in airway inflammation and asthma. However, the magnitude of effect of anti-LTs is smaller than that of corticosteroids, and there is more variability in benefit of LT blockade than is seen with inhaled steroids. In addition, adding anti-LTs to inhaled steroids in asthmatic patients does not appear to produce added anti-inflammatory benefit. Genetic polymorphisms and environmental factors, such as tobacco smoke exposure, might underlie some of the heterogeneity of response to LT blockers.",
keywords = "asthma, Cysteinyl leukotrienes, inflammation",
author = "Yoshiko Ogawa and William Calhoun",
year = "2006",
month = "10",
doi = "10.1016/j.jaci.2006.08.009",
language = "English (US)",
volume = "118",
pages = "789--798",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - The role of leukotrienes in airway inflammation

AU - Ogawa, Yoshiko

AU - Calhoun, William

PY - 2006/10

Y1 - 2006/10

N2 - Cysteinyl leukotrienes (cysLTs) are a class of closely structurally related lipid molecules, originally described as slow-reacting substance of anaphylaxis, with a myriad of biologic functions. These activities include producing smooth muscle contraction and mucus secretion, recruiting allergic inflammatory cells, modulating cytokine production, influencing neural transmission, and altering structural changes in the airway. Administration of cysLTs to animals and human subjects reproduces many features of allergic inflammation and asthma. Leukotriene (LT) blockers have independent efficacy in asthma and improve pulmonary function when added to inhaled steroids. Conversely, blockade of this pathway both in animals and in human subjects results in important reductions in inflammation and its consequences and might reduce structural changes of remodeling. These data collectively make a compelling case for an important role of cysLTs in airway inflammation and asthma. However, the magnitude of effect of anti-LTs is smaller than that of corticosteroids, and there is more variability in benefit of LT blockade than is seen with inhaled steroids. In addition, adding anti-LTs to inhaled steroids in asthmatic patients does not appear to produce added anti-inflammatory benefit. Genetic polymorphisms and environmental factors, such as tobacco smoke exposure, might underlie some of the heterogeneity of response to LT blockers.

AB - Cysteinyl leukotrienes (cysLTs) are a class of closely structurally related lipid molecules, originally described as slow-reacting substance of anaphylaxis, with a myriad of biologic functions. These activities include producing smooth muscle contraction and mucus secretion, recruiting allergic inflammatory cells, modulating cytokine production, influencing neural transmission, and altering structural changes in the airway. Administration of cysLTs to animals and human subjects reproduces many features of allergic inflammation and asthma. Leukotriene (LT) blockers have independent efficacy in asthma and improve pulmonary function when added to inhaled steroids. Conversely, blockade of this pathway both in animals and in human subjects results in important reductions in inflammation and its consequences and might reduce structural changes of remodeling. These data collectively make a compelling case for an important role of cysLTs in airway inflammation and asthma. However, the magnitude of effect of anti-LTs is smaller than that of corticosteroids, and there is more variability in benefit of LT blockade than is seen with inhaled steroids. In addition, adding anti-LTs to inhaled steroids in asthmatic patients does not appear to produce added anti-inflammatory benefit. Genetic polymorphisms and environmental factors, such as tobacco smoke exposure, might underlie some of the heterogeneity of response to LT blockers.

KW - asthma

KW - Cysteinyl leukotrienes

KW - inflammation

UR - http://www.scopus.com/inward/record.url?scp=33749339943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749339943&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2006.08.009

DO - 10.1016/j.jaci.2006.08.009

M3 - Article

VL - 118

SP - 789

EP - 798

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -